Derm-Biome Pharmaceuticals’ topical therapy shows positive results in preclinical skin cancer trial: drug prevents the development of precancerous skin conditions and treats existing skin cancers with no observable side effects
The rates of precancerous skin conditions and skin cancers are soaring in many parts of the world. Actinic keratosis (AK) is the most common form of precancer, with over 40 million Americans a year developing this condition. Treating AKs before…
AVAVA™ Announces the Launch of MIRIA™ at ASLMS 2024 the Energy-Based Medicine & Science Conference
AVAVA™, an innovative aesthetics company focused on becoming a portal to the future of skin vitality, today announces the official launch of MIRIA™ by AVAVA. In addition, through an exclusive distribution partnership with Jeisys, MIRIA will be available in Korea…
Cureskin secures USD 20 million in Series B funding led by HealthQuad with participation from existing investors including JSW Ventures, Khosla Ventures and Sharrp Ventures
Cureskin, an AI-driven dermatology platform that provides clinically validated skin & hair health solutions, has raised Series B funding of USD 20 million. The round was led by India’s leading digital health-focused venture capital fund, HealthQuad along with participation from…
Menarini India strengthens its Dermatology portfolio. Enters into an exclusive partnership agreement with Pierre Fabre Laboratories to market Global brands Eau Thermale Avene and Ducray in India
A. Menarini India Private Limited (‘Menarini India’), a leading Italian pharmaceutical company strengthens its presence in dermatology, and has solidified its strategic position by entering into an exclusive partnership with esteemed French pharmaceutical giant – Pierre Fabre Laboratories. Pierre Fabre…
Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) today announces initiation of the Phase III clinical trial of fatty acid synthase (FASN) inhibitor ASC40 (Denifanstat) for treatment of moderate to severe acne vulgaris. This Phase III clinical trial is a randomized, double-blind,…
Crown Aesthetics Announces Launch Expansion of BIOJUVE™ Living Skin Biome Care into the United Kingdom, Ireland, and Germany
Crown Aesthetics (“Crown”), a division of Crown Laboratories, Inc., is excited to announce the launch of its newest innovation, BIOJUVE™, in the United Kingdom, Ireland and Germany, the largest aesthetic market in Europe. BIOJUVE is a novel skin biome brand…
